Substituted Oxysterol Compositions for NMDA Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new oxysterols that modulate NMDA receptor function to prevent and treat conditions associated with NMDA expression and function, including psychiatric disorders and CNS-related conditions.
Innovation Solution
Development of substituted oxysterols, represented by specific chemical formulas, which act as modulators of NMDA receptors to address these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If existing oxysterols are used to modulate NMDA receptors, then therapeutic effect is achieved, but structural diversity and optimization opportunities are limited
Solution Approach 1:
The patent applies parameter changes by systematically varying chemical parameters of the oxysterol structure, including substituting R1-R6 groups with different functional moieties (alkyl, aryl, heteroaryl, carbocyclyl, heterocyclyl), adjusting stereochemistry at chiral centers, and modifying the core sterol skeleton. This generates a diverse library of compounds with optimized NMDA receptor modulating activity while maintaining therapeutic efficacy.
Solution Approach 2:
The patent creates composite molecular structures by combining the core oxysterol skeleton with various functional groups and substituents at different positions (R1-R6). This results in hybrid molecules that integrate the beneficial properties of the parent oxysterol structure with the specific activities of the attached functional moieties, achieving both structural diversity and reliable therapeutic effect.
2Adaptability or versatility
If new substituted oxysterols are developed to treat broader disorders, then treatment versatility improves, but compound complexity increases
Solution Approach 1:
The patent designs oxysterol compounds with universal structural features that enable them to modulate NMDA receptors across different tissue types and disorder states. The core sterol structure with variable substituents (R1-R6) provides a platform where a single molecular framework can be adapted for multiple therapeutic applications, including psychiatric disorders, CNS conditions, and NMDA-mediated disorders, without requiring entirely new compound classes for each indication.
Solution Approach 2:
The patent applies local quality by making specific modifications at particular positions in the oxysterol molecule (R1-R6) to optimize activity for specific disorders while maintaining the overall therapeutic profile. This allows targeted optimization at key functional sites without redesigning the entire molecule, thereby managing compound complexity while expanding treatment scope.
Data Source
AI summary
Compounds are provided according to Formula (I):and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.